LUCD (Lucid Diagnostics) Valuation Rank


LUCD Lucid Diagnostics Inc LUCD
26 GF Score
Price $1.07
GF Value $0.81
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Lucid Diagnostics Valuation Rank Related Terms

LUCD
26GF Score
Lucid Diagnostics Inc LUCD
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.07 is trading 31.5% above its estimated GF Value™ of $0.81. GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.

Key valuation signals for LUCD:

  • Valuation Rank:
  • GF Value™: $0.81 vs. price of $1.07 (31.5% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score

Get the complete analysis for LUCD

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price
$0.81
GF Value